@beadolive37
actief 15 uren, 22 minuten geleden
Intraperitoneal bevacizumab safe and well tolerated for treating malignant ascites, and the MTD was not reached at doses of 2.5 to 7.5 mg/kg. Intraperitoneal bevacizumab at 7.5 mg/kg weekly is recommended for further study to verify its anti-tumor activity.
Clinical Trials NCT01852409.
Intraperitoneal bevacizumab safe and well tol […] Bekijken
Vrienden
Sorry, er zijn geen leden gevonden.